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Figure 2. Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications, United States, 2018 


































HPV–Female6 3 doses through age 26 yrs
HPV–Male6









Hib11 3 doses HSCT  recipients only
Recommended for adults who meet the  
age requirement, lack documentation of 
vaccination, or lack evidence of past infection
Recommended for adults with other 
indications Contraindicated No recommendation
3 doses
2 or 3 doses depending on vaccine
1 dose
1 dose
1, 2, or 3 doses depending on indication
2 or 3 doses depending on vaccine
1 or 2 doses depending on indication , then booster every 5 yrs if risk remains
2 doses RZV at age >50 yrs (preferred)
contraindicated
contraindicated
1 or 2 doses depending on indication
2 or 3 doses through age 26 yrs
2 doses
3 doses through age 26 yrs
1 dose annually
1 dose Tdap, then Td booster every 10 yrs
2 or 3 doses through age 21 yrs
1 dose ZVL at age >60 yrscontraindicated
or or
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Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2018
This figure should be reviewed with the accompanying footnotes. This figure and the footnotes describe indications for which vaccines, if not previously administered, should be administered unless noted otherwise.


















2 doses RZV (preferred)
1 dose
1 dose
2 or 3 doses depending on age at series initiation
2 or 3 doses depending on age at series initiation
1 or 2 doses depending on indication (if born in 1957 or later)
1 dose Tdap, then Td booster every 10 yrs
1 or 2 doses depending on indication
2 or 3 doses depending on vaccine
3 doses
2 doses
1 or 2 doses depending on indication, then booster every 5 yrs if risk remains
2 or 3 doses depending on vaccine
1 or 3 doses depending on indication
Recommended for adults who meet the  
age requirement, lack documentation of 
vaccination, or lack evidence of past infection
Recommended for adults with other 
indications No recommendation
or or
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• Administer 1 dose of age-appropriate inactivated influenza 
vaccine (IIV) or recombinant influenza vaccine (RIV) annually
• Live attenuated influenza vaccine (LAIV) is not recommended 
for the 2017–2018 influenza season
• A list of currently available influenza vaccines is available at  
www.cdc.gov/flu/protect/vaccine/vaccines.htm
Special populations
• Administer age-appropriate IIV or RIV to: 
 ʱ Pregnant women
 ʱ Adults with hives-only egg allergy
 ʱ Adults with egg allergy other than hives (e.g., 
angioedema or respiratory distress): Administer IIV or RIV 
in a medical setting under supervision of a health care 
provider who can recognize and manage severe allergic 
conditions
2. Tetanus, diphtheria, and pertussis vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/tdap-td.html 
General information
• Administer to adults who previously did not receive a dose 
of tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis vaccine (Tdap) as an adult or child (routinely 
recommended at age 11–12 years) 1 dose of Tdap, followed 
by a dose of tetanus and diphtheria toxoids (Td) booster 
every 10 years
• Information on the use of Tdap or Td as tetanus prophylaxis 
in wound management is available at www.cdc.gov/mmwr/
preview/mmwrhtml/rr5517a1.htm
Special populations
• Pregnant women: Administer 1 dose of Tdap during each 
pregnancy, preferably in the early part of gestational weeks 
27–36
3. Measles, mumps, and rubella vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html 
General information
• Administer 1 dose of measles, mumps, and rubella vaccine 
(MMR) to adults with no evidence of immunity to measles, 
mumps, or rubella
• Evidence of immunity is:
 ʱ Born before 1957 (except for health care personnel, see 
below)
 ʱ Documentation of receipt of MMR
 ʱ Laboratory evidence of immunity or disease
• Documentation of a health care provider-diagnosed disease 
without laboratory confirmation is not considered evidence 
of immunity
Special populations
• Pregnant women and nonpregnant women of 
childbearing age with no evidence of immunity to rubella: 
Administer 1 dose of MMR (if pregnant, administer MMR after 
pregnancy and before discharge from health care facility)
• HIV infection and CD4 cell count ≥200 cells/μL for at least 
6 months and no evidence of immunity to measles, mumps, 
or rubella: Administer 2 doses of MMR at least 28 days apart 
• Students in postsecondary educational institutions, 
international travelers, and household contacts of 
immunocompromised persons: Administer 2 doses of 
MMR at least 28 days apart (or 1 dose of MMR if previously 
administered 1 dose of MMR)
• Health care personnel born in 1957 or later with no 
evidence of immunity: Administer 2 doses of MMR at least 
28 days apart for measles or mumps, or 1 dose of MMR for 
rubella (if born before 1957, consider MMR vaccination)
• Adults who previously received ≤2 doses of mumps-
containing vaccine and are identified by public health 
authority to be at increased risk for mumps in an 
outbreak: Administer 1 dose of MMR





• Administer to adults without evidence of immunity to 
varicella 2 doses of varicella vaccine (VAR) 4–8 weeks apart 
if previously received no varicella-containing vaccine (if 
previously received 1 dose of varicella-containing vaccine, 
administer 1 dose of VAR at least 4 weeks after the first dose)  
• Evidence of immunity to varicella is:
 ʱ U.S.-born before 1980 (except for pregnant women and 
health care personnel, see below)
 ʱ Documentation of receipt of 2 doses of varicella or 
varicella-containing vaccine at least 4 weeks apart
 ʱ Diagnosis or verification of history of varicella or herpes 
zoster by a health care provider
 ʱ Laboratory evidence of immunity or disease
Special populations
• Administer 2 doses of VAR 4–8 weeks apart if previously 
received no varicella-containing vaccine (if previously 
received 1 dose of varicella-containing vaccine, administer 1 
dose of VAR at least 4 weeks after the first dose) to:
 ʱ Pregnant women without evidence of immunity: 
Administer the first of the 2 doses or the second dose after 
pregnancy and before discharge from health care facility
 ʱ Health care personnel without evidence of immunity
• Adults with HIV infection and CD4 cell count ≥200 cells/μL: 
May administer, based on individual clinical decision, 2 doses 
of VAR 3 months apart





• Administer 2 doses of recombinant zoster vaccine (RZV) 2–6 
months apart to adults aged 50 years or older regardless of 
past episode of herpes zoster or receipt of zoster vaccine live 
(ZVL)
• Administer 2 doses of RZV 2–6 months apart to adults who 
previously received ZVL at least 2 months after ZVL
• For adults aged 60 years or older, administer either RZV or 
ZVL (RZV is preferred)
Special populations
• ZVL is contraindicated for pregnant women and adults with 
severe immunodeficiency
6. Human papillomavirus vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html 
General information
• Administer human papillomavirus (HPV) vaccine to females 
through age 26 years and males through age 21 years 
(males aged 22 through 26 years may be vaccinated based 
on individual clinical decision)  
• The number of doses of HPV vaccine to be administered 
depends on age at initial HPV vaccination
 ʱ No previous dose of HPV vaccine: Administer 3-dose 
series at 0, 1–2, and 6 months (minimum intervals: 4 weeks 
between doses 1 and 2, 12 weeks between doses 2 and 3, 
and 5 months between doses 1 and 3; repeat doses if given 
too soon)
 ʱ Aged 9–14 years at HPV vaccine series initiation and 
received 1 dose or 2 doses less than 5 months apart: 
Administer 1 dose
 ʱ Aged 9–14 years at HPV vaccine series initiation and 
received 2 doses at least 5 months apart: No additional 
dose is needed
Special populations
• Adults with immunocompromising conditions (including 
HIV infection) through age 26 years: Administer 3-dose 
series at 0, 1–2, and 6 months
• Men who have sex with men through age 26 years: 
Administer 2- or 3-dose series depending on age at initial 
vaccination (see above); if no history of HPV vaccine, 
administer 3-dose series at 0, 1–2, and 6 months
• Pregnant women through age 26 years: HPV vaccination 
is not recommended during pregnancy, but there is no 
evidence that the vaccine is harmful and no intervention 
needed for women who inadvertently receive HPV vaccine 
while pregnant; delay remaining doses until after pregnancy; 




• Administer to immunocompetent adults aged 65 years or 
older 1 dose of 13-valent pneumococcal conjugate vaccine 
(PCV13), if not previously administered, followed by 1 
dose of 23-valent pneumococcal polysaccharide vaccine 
(PPSV23) at least 1 year after PCV13; if PPSV23 was previously 
administered but not PCV13, administer PCV13 at least 1 year 
after PPSV23
• When both PCV13 and PPSV23 are indicated, administer 
PCV13 first (PCV13 and PPSV23 should not be administered 
during the same visit); additional information on vaccine 
timing is available at www.cdc.gov/vaccines/vpd/pneumo/
downloads/pneumo-vaccine-timing.pdf
Special populations
• A minister to adults aged 19 through 64 years with the 
following chronic conditions 1 dose of PPSV23 (at age 65 
years or older, administer 1 dose of PCV13, if not previously 
received, and another dose of PPSV23 at least 1 year after 
PCV13 and at least 5 years after PPSV23):
 ʱ Chronic heart disease (excluding hypertension)
 ʱ Chronic lung disease
 ʱ Chronic liver disease
 ʱ Alcoholism
 ʱ Diabetes mellitus
 ʱ Cigarette smoking
• Administer to adults aged 19 years or older with the 
following indications 1 dose of PCV13 followed by 1 dose of 
PPSV23 at least 8 weeks after PCV13, and a second dose of 
PPSV23 at least 5 years after the first dose of PPSV23 (if the 
most recent dose of PPSV23 was administered before age 65 
years, at age 65 years or older, administer another dose of 
PPSV23 at least 5 years after t e last dose of PPSV23):
 ʱ Immunodeficien y disorders (in luding B- and 
T-lymphocyte deficiency, compleme t deficiencies, and 
phagocytic disorders)
 ʱ HIV infection
 ʱ Anato ical or functional asplenia (including sickle cell 
disease and other hemoglobinopathies) 
 ʱ Chronic renal failure and nephrotic syndrome
• Administer to adults aged 19 years or older with the 
following indications 1 dose of PCV13 followed by 1 dose of 
PPSV23 at least 8 weeks after PCV13 (if the dose of PPSV23 
was administered before age 65 years, at age 65 years or 
older, administer another dose of PPSV23 at least 5 years 
after the last dose of PPSV23):
 ʱ Cerebrospinal fluid leak
 ʱ Cochlear implant
8. Hepatitis A vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html 
General information
• Administer to adults who have a specific risk (see below), 
or lack a risk factor but want protection, 2-dose series of 
single antigen hepatitis A vaccine (HepA; Havrix at 0 and 
6–12 months or Vaqta at 0 and 6–18 months; minimum 
interval: 6 months) or a 3-dose series of combined hepatitis 
A and hepatitis B vaccine (HepA-HepB) at 0, 1, and 6 months; 
minimum intervals: 4 weeks between first and second doses, 
5 months between second and third doses
Special populations
• Administer HepA or HepA-HepB to adults with the following 
indications:
 ʱ Travel to or work in countries with high or intermediate 
hepatitis A endemicity 
 ʱ Men who have sex with men
 ʱ Injection or noninjection drug use
 ʱ Work with hepatitis A virus in a research laboratory 
or with nonhuman primates infected with hepatitis A 
virus
 ʱ Clotting factor disorders
 ʱ Chronic liver disease
Close, personal contact with an international adoptee 
( .g., household or regular babysitting) during the first 60 
ays after arrival in the United States from a country with 
high or intermediate endemicity (administer the first dose 
as soon as the adoption is planned)
 ʱ Healthy adults through age 40 years who have recently 
been exposed to hepatitis A virus; adults older than age 
40 years may receive HepA or HepA-HepB if hepatitis A 
immunoglobulin cannot be obtained
9. Hepatitis B vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html 
Gen ral informatio
• Administer to adults who have a specific risk (see below), or 
lack a risk factor but want protection, 3-dose series of single 
antigen hepatitis B vaccine (HepB) or combined hepatitis A 
and hepatitis B vaccine (HepA-HepB) at 0, 1, and 6 months 
(minimum intervals: 4 weeks b tween doses 1 and 2 for 
HepB and HepA-HepB; between doses 2 and 3, 8 weeks for 
HepB and 5 months for HepA-HepB)
Special populations
• Administer HepB or HepA-HepB to adults with the following 
indications:
 ʱ Chronic liver disease (e.g., hepatitis C infection, cirrhosis, 
fatty liver disease, alcoholic liver disease, autoimmune 
hepatitis, alanine aminotransferase [ALT] or aspartate 
aminotransferase [AST] level greater than twice the upper 
limit of normal)
 ʱ HIV infection
 ʱ Percutaneous or mucosal risk of exposure to blood 
(e.g., household contacts of hepatitis B surface antigen 
[HBsAg]-positive persons; adults younger than age 60 
years with diabetes mellitus or aged 60 years or older 
with diabetes mellitus based on individual clinical decision; 
adults in predialysis care or receiving hemodialysis or 
peritoneal dialysis; recent or current injection drug 
users; health care and public safety workers at risk for 
exposure to blood or blood-contaminated body fluids)
 ʱ Sexual exposure risk (e.g., sex partners of HBsAg-
positive persons; sexually active persons not in a mutually 
monogamous relationship; persons seeking evaluation or 
treatment for a sexually transmitted infection; and men 
who have sex with men [MSM])
 ʱ Receive care in settings where a high proportion of 
adults have risks for hepatitis B infection (e.g., facilities 
providing sexually transmitted disease treatment, drug-
abuse treatment and prevention services, hemodialysis 
and end-stage renal disease programs, institutions for 
developmentally disabled persons, health care settings 
targeting services to injection drug users or MSM, HIV 
testing and treatment facilities, and correctional facilities)




Special populations: Serogroups A, C, W, and Y 
meningococcal vaccine (MenACWY)
• Administer 2 doses of MenACWY at least 8 weeks apart and 
revaccinate with 1 dose of MenACWY every 5 years, if the risk 
remains, to adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease and other hemoglobinopathies)
 ʱ HIV infection
 ʱ Persistent complement component deficiency
 ʱ Eculizumab use
• Administer 1 dose of MenACWY and revaccinate with 1 dose 
of MenACWY every 5 years, if the risk remains, to adults with 
the following indications:
 ʱ Travel to or live in countries where meningococcal 
disease is hyperendemic or epidemic, including 
countries in the African meningitis belt or during the Hajj
 ʱ At risk from a meningococcal disease outbreak 
attributed to serogroup A, C, W, or Y
 ʱ Microbiologists routinely exposed to Neisseria 
meningitidis
 ʱ Military recruits
 ʱ First-year college students who live in residential 
housing (if they did not receive MenACWY at age 16 years 
or older)
General Information: Serogroup B meningococcal vaccine 
(MenB)
 ʱ May administer, based on individual clinical decision, to 
young adults and adolescents aged 16–23 years (preferred 
age is 16–18 years) who are not at increased risk 2-dose 
series of MenB-4C (Bexsero) at least 1 month apart or 
2-dose series of MenB-FHbp (Trumenba) at least 6 months 
apart
 ʱ MenB-4C and MenB-FHbp are not interchangeable
Special populations: MenB
• Administer 2-dose series of MenB-4C at least 1 month apart 
or 3-dose series of MenB-FHbp at 0, 1–2, and 6 months to 
adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease)
 ʱ Persistent complement component deficiency
 ʱ Eculizumab use
 ʱ At risk from a meningococcal disease outbreak 
attributed to serogroup B
 ʱ Microbiologists routinely exposed to Neisseria 
meningitidis
11.  Haemophilus influenzae type b vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html 
Special populations
• Administer Haemophilus influenzae type b vaccine (Hib) to 
adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease) or undergoing elective splenectomy: Administer 
1 dose  if not previously vaccinated (preferably at least 14 
days before elective splenectomy)
 ʱ Hematopoietic stem cell transplant (HSCT): Administer 
3-dose series with doses 4 weeks apart starting 6 to 12 
months after successful transplant regardless of Hib 
vaccination history
Footnotes. Recommended immunization schedule for adults aged 19 years or older, United States, 2018




• Administer 1 dose of age-appropriate inactivated influenza 
vaccine (IIV) or recombinant influenza vaccine (RIV) annually
• Live attenuated influenza vaccine (LAIV) is not recommended 
for the 2017–2018 influenza season
• A list of currently available influenza vaccines is available at  
www.cdc.gov/flu/protect/vaccine/vaccines.htm
Special populations
• Administer age-appropriate IIV or RIV to: 
 ʱ Pregnant women
 ʱ Adults with hives-only egg allergy
 ʱ Adults with egg allergy other than hives (e.g., 
angioedema or respiratory distress): Administer IIV or RIV 
in a medical setting under supervision of a health care 
provider who can recognize and manage severe allergic 
conditions
2. Tetanus, diphtheria, and pertussis vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/tdap-td.html 
General information
• Administer to adults who previously did not receive a dose 
of tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis vaccine (Tdap) as an adult or child (routinely 
recommended at age 11–12 years) 1 dose of Tdap, followed 
by a dose of tetanus and diphtheria toxoids (Td) booster 
every 10 years
• Information on the use of Tdap or Td as tetanus prophylaxis 
in wound management is available at www.cdc.gov/mmwr/
preview/mmwrhtml/rr5517a1.htm
Special populations
• Pregnant women: Administer 1 dose of Tdap during each 
pregnancy, preferably in the early part of gestational weeks 
27–36
3. Measles, mumps, and rubella vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html 
General information
• Administer 1 dose of measles, mumps, and rubella vaccine 
(MMR) to adults with no evidence of immunity to measles, 
mumps, or rubella
• Evidence of immunity is:
 ʱ Born before 1957 (except for health care personnel, see 
below)
 ʱ Documentation of receipt of MMR
 ʱ Laboratory evidence of immunity or disease
• Documentation of a health care provider-diagnosed disease 
without laboratory confirmation is not considered evidence 
of immunity
Special populations
• Pregnant women and nonpregnant women of 
childbearing age with no evidence of immunity to rubella: 
Administer 1 dose of MMR (if pregnant, administer MMR after 
pregnancy and before discharge from health care facility)
• HIV infection and CD4 cell count ≥200 cells/μL for at least 
6 months and no evidence of immunity to measles, mumps, 
or rubella: Administer 2 doses of MMR at least 28 days apart 
• Students in postsecondary educational institutions, 
international travelers, and household contacts of 
immunocompromised persons: Administer 2 doses of 
MMR at least 28 days apart (or 1 dose of MMR if previously 
administered 1 dose of MMR)
• Health care personnel born in 1957 or later with no 
evidence of immunity: Administer 2 doses of MMR at least 
28 days apart for measles or mumps, or 1 dose of MMR for 
rubella (if born before 1957, consider MMR vaccination)
• Adults who previously received ≤2 doses of mumps-
containing vaccine and are identified by public health 
authority to be at increased risk for mumps in an 
outbreak: Administer 1 dose of MMR





• Administer to adults without evidence of immunity to 
varicella 2 doses of varicella vaccine (VAR) 4–8 weeks apart 
if previously received no varicella-containing vaccine (if 
previously received 1 dose of varicella-containing vaccine, 
administer 1 dose of VAR at least 4 weeks after the first dose)  
• Evidence of immunity to varicella is:
 ʱ U.S.-born before 1980 (except for pregnant women and 
health care personnel, see below)
 ʱ Documentation of receipt of 2 doses of varicella or 
varicella-containing vaccine at least 4 weeks apart
 ʱ Diagnosis or verification of history of varicella or herpes 
zoster by a health care provider
 ʱ Laboratory evidence of immunity or disease
Special populations
• Administer 2 doses of VAR 4–8 weeks apart if previously 
received no varicella-containing vaccine (if previously 
received 1 dose of varicella-containing vaccine, administer 1 
dose of VAR at least 4 weeks after the first dose) to:
 ʱ Pregnant women without evidence of immunity: 
Administer the first of the 2 doses or the second dose after 
pregnancy and before discharge from health care facility
 ʱ Health care personnel without evidence of immunity
• Adults with HIV infection and CD4 cell count ≥200 cells/μL: 
May administer, based on individual clinical decision, 2 doses 
of VAR 3 months apart





• Administer 2 doses of recombinant zoster vaccine (RZV) 2–6 
months apart to adults aged 50 years or older regardless of 
past episode of herpes zoster or receipt of zoster vaccine live 
(ZVL)
• Administer 2 doses of RZV 2–6 months apart to adults who 
previously received ZVL at least 2 months after ZVL
• For adults aged 60 years or older, administer either RZV or 
ZVL (RZV is preferred)
Special populations
• ZVL is contraindicated for pregnant women and adults with 
severe immuno eficiency
6. Human papillomavirus vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html 
General infor ation
• Administer human papillomavirus (HPV) vaccine to females 
through age 26 years and males through age 21 years 
(males aged 22 through 26 years may be vaccinated based 
on individua  cl nical decision)  
• The number of doses of HPV vaccine to be administered 
depends on age at initial HPV vaccination
 ʱ No previous d se of HPV vaccine: Administer 3-dose 
series a  0, 1–2, and 6 months (minimum intervals: 4 weeks 
between doses 1 and 2, 12 weeks between doses 2 and 3, 
and 5 months between doses 1 and 3; repeat doses if given 
too soon)
 ʱ Aged 9–14 years at HPV vaccine series initiation and 
received 1 dose or 2 doses less than 5 months apart: 
Administer 1 dose
 ʱ Aged 9–14 years at HPV vaccine series initiation and 
received 2 doses at least 5 months apart: No additional 
dose is needed
Special populations
• Adults with immunocompromising conditions (including 
HIV infection) through age 26 years: Administer 3-dose 
series at 0, 1–2, and 6 months
• Men who have sex with men through age 26 years: 
Administer 2- or 3-dose series depending on age at initial 
vaccination (see above); if no history of HPV vaccine, 
administer 3-dose series at 0, 1–2, and 6 months
• Pregnant women through age 26 years: HPV vaccination 
is not recommended during pregnancy, but there is no 
evidence that the vaccine is harmful and no intervention 
needed for women who inadvertently receive HPV vaccine 
while pregnant; delay remaining doses until after pregnancy; 




• Administer to immunocompetent adults aged 65 years or 
older 1 dose of 13-valent pneumococcal conjugate vaccine 
(PCV13), if not previously administered, followed by 1 
dose of 23-valent pneumococcal polysaccharide vaccine 
(PPSV23) at least 1 year after PCV13; if PPSV23 was previously 
administered but not PCV13, administer PCV13 at least 1 year 
after PPSV23
• When both PCV13 and PPSV23 are indicated, administer 
PCV13 first (PCV13 and PPSV23 should not be administered 
during the same visit); additional information on vaccine 
timing is available at www.cdc.gov/vaccines/vpd/pneumo/
downloads/pneumo-vaccine-timing.pdf




• Administer 1 dose of age-appropriate inactivated influenza 
vaccine (IIV) or recombinant influenza vaccine (RIV) annually
• Live attenuated influenza vaccine (LAIV) is not recommended 
for the 2017–2018 influenza season
• A list of currently available influenza vaccines is available at  
www.cdc.gov/flu/protect/vaccine/vaccines.htm
Special populations
• Administer age-appropriate IIV or RIV to: 
 ʱ Pregnant women
 ʱ Adults with hives-only egg allergy
 ʱ Adults with egg allergy other than hives (e.g., 
angioedema or respiratory distress): Administer IIV or RIV 
in a medical setting under supervision of a health care 
provider who can recognize and manage severe allergic 
conditions
2. Tetanus, diphtheria, and pertussis vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/tdap-td.html 
General information
• Administer to adults who previously did not receive a dose 
of tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis vaccine (Tdap) as an adult or child (routinely 
recommended at age 11–12 years) 1 dose of Tdap, followed 
by a dose of tetanus and diphtheria toxoids (Td) booster 
every 10 years
• Information on the use of Tdap or Td as tetanus prophylaxis 
in wound management is available at www.cdc.gov/mmwr/
preview/mmwrhtml/rr5517a1.htm
Special populations
• Pregnant women: Administer 1 dose of Tdap during each 
pregnancy, preferably in the early part of gestational weeks 
27–36
3. Measles, mumps, and rubella vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html 
General information
• Administer 1 dose of measles, mumps, and rubella vaccine 
(MMR) to adults with no evidence of immunity to measles, 
mumps, or rubella
• Evidence of immunity is:
 ʱ Born before 1957 (except for health care personnel, see 
below)
 ʱ Documentation of receipt of MMR
 ʱ Laboratory evidence of immunity or disease
• Documentation of a health care provider-diagnosed disease 
without laboratory confirmation is not considered evidence 
of immunity
Special populations
• Pregnant women and nonpregnant women of 
childbearing age with no evidence of immunity to rubella: 
Administer 1 dose of MMR (if pregnant, administer MMR after 
pregnancy and before discharge from health care facility)
• HIV infection and CD4 cell count ≥200 cells/μL for at least 
6 months and no evidence of immunity to measles, mumps, 
or rubella: Administer 2 doses of MMR at least 28 days apart 
• Students in postsecondary educational institutions, 
international travelers, and household contacts of 
immunocompromised persons: Administer 2 doses of 
MMR at least 28 days apart (or 1 dose of MMR if previously 
administered 1 dose of MMR)
• Health care personnel born in 1957 or later with no 
evidence of immunity: Administer 2 doses of MMR at least 
28 days apart for measles or mumps, or 1 dose of MMR for 
rubella (if born before 1957, consider MMR vaccination)
• Adults who previously received ≤2 doses of mumps-
containing vaccine and are identified by public health 
authority to be at increased risk for mumps in an 
outbreak: Administer 1 dose of MMR





• Administer to adults without evidence of immunity to 
varicella 2 doses of varicella vaccine (VAR) 4–8 weeks apart 
if previously received no varicella-containing vaccine (if 
previously received 1 dose of varicella-containing vaccine, 
administer 1 dose of VAR at least 4 weeks after the first dose)  
• Evidence of immunity to varicella is:
 ʱ U.S.-born before 1980 (except for pregnant women and 
health care personnel, see below)
 ʱ Documentation of receipt of 2 doses of varicella or 
varicella-containing vaccine at least 4 weeks apart
 ʱ Diagnosis or verification of history of varicella or herpes 
zoster by a health care provider
 ʱ Laboratory evidence of immunity or disease
Special populations
• Administer 2 doses of VAR 4–8 weeks apart if previously 
received no varicella-containing vaccine (if previously 
received 1 dose of varicella-containing vaccine, administer 1 
dose of VAR at least 4 weeks after the first dose) to:
 ʱ Pregnant women without evidence of immunity: 
Administer the first of the 2 doses or the second dose after 
pregnancy and before discharge from health care facility
 ʱ Health care personnel without evidence of immunity
• Adults with HIV infection and CD4 cell count ≥200 cells/μL: 
May administer, based on individual clinical decision, 2 doses 
of VAR 3 months apart





• Administer 2 doses of recombinant zoster vaccine (RZV) 2–6 
months apart to adults aged 50 years or older regardless of 
past episode of herpes zoster or receipt of zoster vaccine live 
(ZVL)
• Administer 2 doses of RZV 2–6 months apart to adults who 
previously received ZVL at least 2 months after ZVL
• For adults aged 60 years or older, administer either RZV or 
ZVL (RZV is preferred)
Special populations
• ZVL is contraindicated for pregnant women and adults with 
severe immunodeficiency
6. Human papillomavirus vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html 
General information
• Administer human papillomavirus (HPV) vaccine to females 
through age 26 years and males through age 21 years 
(males aged 22 through 26 years may be vaccinated based 
on individual clinical decision)  
• The number of doses of HPV vaccine to be administered 
depends on age at initial HPV vaccination
 ʱ No previous dose of HPV vaccine: Administer 3-dose 
series at 0, 1–2, and 6 months (minimum intervals: 4 weeks 
between doses 1 and 2, 12 weeks between doses 2 and 3, 
and 5 months between doses 1 and 3; repeat doses if given 
too soon)
 ʱ Aged 9–14 years at HPV vaccine series initiation and 
received 1 dose or 2 doses less than 5 months apart: 
Administer 1 dose
 ʱ Aged 9–14 years at HPV vaccine series initiation and 
received 2 doses at least 5 months apart: No additional 
dose is needed
Special populations
• Adults with immunocompromising conditions (including 
HIV infection) through age 26 years: Administer 3-dose 
series at 0, 1–2, and 6 months
• Men who have sex with men through age 26 years: 
Administer 2- or 3-dose series depending on age at initial 
vaccination (see above); if no history of HPV vaccine, 
administer 3-dose series at 0, 1–2, and 6 months
• Pregnant women through age 26 years: HPV vaccination 
is not recommended during pregnancy, but there is no 
evidence that the vaccine is harmful and no intervention 
needed for women who inadvertently receive HPV vaccine 
while pregnant; delay remaining doses until after pregnancy; 




• Administer to immunocompetent adults aged 65 years or 
older 1 dose of 13-valent pneumococcal conjugate vaccine 
(PCV13), if not previously administered, followed by 1 
dose of 23-valent pneumococcal polysaccharide vaccine 
(PPSV23) at least 1 year after PCV13; if PPSV23 was previously 
administered but not PCV13, administer PCV13 at least 1 year 
after PPSV23
• When both PCV13 and PPSV23 are indicated, administer 
PCV13 first (PCV13 and PPSV23 should not be administered 
during the same visit); additional information on vaccine 
timing is available at www.cdc.gov/vaccines/vpd/pneumo/
downloads/pneumo-vaccine-timing.pdf




• Administer 1 dose of age-appropriate inactivated influenza 
vaccine (IIV) or recombinant influenza vaccine (RIV) annually
• Live attenuated influenza vaccine (LAIV) is not recommended 
for the 2017–2018 influenza season
• A list of currently available influenza vaccines is available at  
www.cdc.gov/flu/protect/vaccine/vaccines.htm
Special populations
• Administer age-appropriate IIV or RIV to: 
 ʱ Pregnant women
 ʱ Adults with hives-only egg allergy
 ʱ Adults with egg allergy other than hives (e.g., 
angioedema or respiratory distress): Administer IIV or RIV 
in a medical setting under supervision of a health care 
provider who can recognize and manage severe allergic 
conditions
2. Tetanus, diphtheria, and pertussis vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/tdap-td.html 
General information
• Administer to adults who previously did not receive a dose 
of tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis vaccine (Tdap) as an adult or child (routinely 
recommended at age 11–12 years) 1 dose of Tdap, followed 
by a dose of tetanus and diphtheria toxoids (Td) booster 
every 10 years
• Information on the use of Tdap or Td as tetanus prophylaxis 
in wound management is available at www.cdc.gov/mmwr/
preview/mmwrhtml/rr5517a1.htm
Special populations
• Pregnant women: Administer 1 dose of Tdap during each 
pregnancy, preferably in the early part of gestational weeks 
27–36
3. Measles, mumps, and rubella vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html 
General information
• Administer 1 dose of measles, mumps, and rubella vaccine 
(MMR) to adults with no evidence of immunity to measles, 
mumps, or rubella
• Evidence of immunity is:
 ʱ Born before 1957 (except for health care personnel, see 
below)
 ʱ Documentation of receipt of MMR
 ʱ Laboratory evidence of immunity or disease
• Documentation of a health care provider-diagnosed disease 
without laboratory confirmation is not considered evidence 
of immunity
Special populations
• Pregnant women and nonpregnant women of 
childbearing age with no evidence of immunity to rubella: 
Administer 1 dose of MMR (if pregnant, administer MMR after 
pregnancy and before discharge from health care facility)
• HIV infection and CD4 cell count ≥200 cells/μL for at least 
6 months and no evidence of immunity to measles, mumps, 
or rubella: Administer 2 doses of MMR at least 28 days apart 
• Students in postsecondary educational institutions, 
international travelers, and household contacts of 
immunocompromised persons: Administer 2 doses of 
MMR at least 28 days apart (or 1 dose of MMR if previously 
administered 1 dose of MMR)
• Health care personnel born in 1957 or later with no 
evidence of immunity: Administer 2 doses of MMR at least 
28 days apart for measles or mumps, or 1 dose of MMR for 
rubella (if born before 1957, consider MMR vaccination)
• Adults who previously received ≤2 doses of mumps-
containing vaccine and are identified by public health 
authority to be at increased risk for mumps in an 
outbreak: Administer 1 dose of MMR





• Administer to adults without evidence of immunity to 
varicella 2 doses of varicella vaccine (VAR) 4–8 weeks apart 
if previously received no varicella-containing vaccine (if 
previously received 1 dose of varicella-containing vaccine, 
administer 1 dose of VAR at least 4 weeks after the first dose)  
• Evidence of immunity to varicella is:
 ʱ U.S.-born before 1980 (except for pregnant women and 
health care personnel, see below)
 ʱ Documentation of receipt of 2 doses of varicella or 
varicella-containing vaccine at least 4 weeks apart
 ʱ Diagnosis or verification of history of varicella or herpes 
zoster by a he lth care provider
 ʱ Laboratory evidence of immunity or disease
Special popul s
• Administer 2 doses of VAR 4–8 weeks apart if previo sly 
re eived no vari ella-containing vaccine (if previously 
receiv d 1 dose of varicell -co taining vaccine, ad inister 1 
dose of VAR at least 4 weeks after the first dose) to:
 ʱ Pregnant women without vidence of immunity: 
Administer the first of the 2 doses or the second dose after 
pregnancy and before discharge from health care facility
 ʱ Health care personnel without evidence of immunity
• Adults with HIV infection and CD4 cell count ≥200 cells/μL: 
May administer, based on individual clinical decision, 2 doses 
of VAR 3 months apart





• Administer 2 doses of recombin nt zoster vaccine (RZV) 2–6 
months apart to adults aged 50 years or older regardless of 
past episode of herpes zoster or receipt of zoster vaccine live 
(ZVL)
• Administer 2 doses of RZV 2–6 months apart to adults who 
previously received ZVL at least 2 months after ZVL
• For adults aged 60 years or older, administer either RZV or 
ZVL (RZV is preferred)
Special populations
• ZVL is contraindicated for pregnant women and adults with 
severe immunodeficiency
6. Human papillomavirus vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html 
General information
• Administer human papillomavirus (HPV) vaccine to females 
through age 26 years and males through age 21 years 
(males aged 22 through 26 years may be vaccinated based 
on individual clinical decision)  
• The number of doses of HPV vaccine to be administered 
depends on age at initial HPV vaccination
 ʱ No previous dose of HPV vaccine: Administer 3-dose 
series at 0, 1–2, and 6 months (minimum intervals: 4 weeks 
between doses 1 and 2, 12 weeks between doses 2 and 3, 
and 5 months between doses 1 and 3; repeat doses if given 
too soon)
 ʱ Aged 9–14 years at HPV vaccine series initiation and 
received 1 dose or 2 doses less than 5 months apart: 
Administer 1 dose
 ʱ Aged 9–14 years at HPV vaccine series initiation and 
received 2 doses at least 5 months apart: No additional 
dose is needed
Special populations
• Adults with immunocompromising conditions (including 
HIV infection) through age 26 years: Administer 3-dose 
series t 0, 1–2, and 6 months
• Men who have sex with men through age 26 years: 
Administer 2- or 3-dose s ries depe ding on ge at initial 
vaccination (see above); if no history of HPV vaccine, 
administer 3-dose series at 0, 1–2, and 6 months
• Pregnant women through age 26 years: HPV vaccination 
is not re mended uring pregnancy, but there is no 
evidenc  that the vaccine is harmful and no intervention 
needed for women who inadvertently receive HPV vaccine 
while pregnant; delay remaining doses until after pregnancy; 




• Administer to immunocompetent adults aged 65 years or 
older 1 dose of 13-valent pneumococcal conjugate vaccine 
(PCV13), if not previously administered, followed by 1 
dose of 23-valent pneumococcal polysaccharide vaccine 
(PPSV23) at least 1 year after PCV13; if PPSV23 was previously 
administered but not PCV13, administer PCV13 at least 1 year 
after PPSV23
• When both PCV13 and PPSV23 are indicated, administer 
PCV13 first (PCV13 and PPSV23 should not be administered 
during the same visit); additional information on vaccine 
timing is available at www.cdc.gov/vaccines/vpd/pneumo/
downloads/pneumo-vaccine-timing.pdf
Special populations
• Administer to adults ag d 19 through 64 y rs with the 
following chronic conditions 1 dose of PPSV 3 (at age 65 
years or older, admi ister 1 ose of PCV13, if not previously 
received, and a other dose f PPSV23 at least 1 year after 
PCV13 and at least 5 years aft r PPSV23):
 ʱ Chronic heart disease (excluding hypertension)
 ʱ Chronic lung disease
 ʱ Chronic liver disease
 ʱ Alcoholis
 ʱ Diabetes mellitus
 ʱ Ci arette smoking
• Admi ister to adults aged 19 years or older with the 
following indications 1 dose of PCV13 followed by 1 dose of 
PPSV23 at least 8 weeks after PCV13, and a second dose of 
PPSV23 at least 5 years after the first dose of PPSV23 (if the 
most recent dose of PPSV23 w s administered before age 65 
years, at age 65 years or older, administer another dose of 
PPSV23 at least 5 years after the last dose of PPSV23):
 ʱ Immunodeficiency disorders (including B- and 
T-lymphocyte deficiency, complement deficiencies, and 
phagocytic disorders)
 ʱ HIV infection
 ʱ Anatomical or functional asplenia (including sickle cell 
disease and other hemoglobinopathies) 
 ʱ Chronic renal failure and nephrotic syndrome
• Administer to adults aged 19 years or older with the 
following indications 1 dose of PCV13 followed by 1 dose of 
PPSV23 at least 8 weeks after PCV13 (if the dose of PPSV23 
was administered before age 65 years, at age 65 years or 
older, administer another dose f PPSV23 at le st 5 years 
fter the las  dose of PPSV23):
 ʱ Cerebr spinal fluid leak
 ʱ Cochlear implant
8. Hepatitis A vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html 
General infor ation
• Administer to adults who have a specific risk (see below), 
or lack a risk factor but want protecti n, 2-dose serie  of 
single antigen hepatitis A vaccine (HepA; Havrix at 0 and 
6–12 months or V qt  at 0 and 6–18 months; minimum 
in erval: 6 months) or a 3-dose series of com ined hepatitis 
A and hepatitis B vaccine (HepA-HepB) t 0, 1, and 6 months; 
minimum in vals: 4 w eks be ween first and second doses, 
5 mont s betwe n secon  and third ses
Special populations
• Administer HepA or HepA-HepB to adults with the following 
indications:
 ʱ Travel to or work in countries with high or intermediate 
hepatitis A e demicity 
 ʱ Men who have sex with men
 ʱ Injection or noninjection drug use
 ʱ Work with hepatitis A virus in a research laboratory 
or with nonhuman primates infected with hepatitis A 
virus
 ʱ Clotting factor disorders
 ʱ Chronic liver disease
 ʱ Close, personal contact with an international adoptee 
(e.g., household or regular babysitting) during the first 60 
days after arrival in the United States from a country with 
high or intermediate endemicity (administer the first dose 
as soon as the adoption is planned)
 ʱ Healthy adults through age 40 years who have recently 
been exposed to hepatitis A virus; adults older than age 
40 years may re eive HepA or HepA-HepB if hepatitis A 
immunoglobulin cannot be obtained
9. Hepatitis B vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html 
General infor ation
• Administer to adults who have a specific risk (see below), or 
l ck a risk factor b t want protection, 3-dose series of ingle 
antigen hepatit s B va cine (HepB) or combined hepatitis A 
and hepatitis B vaccine (HepA-HepB) at 0, 1, and 6 months 
(mi imum intervals: 4 weeks between doses 1 and 2 for 
HepB and HepA-HepB; between doses 2 and 3, 8 weeks for 
HepB and 5 months for HepA-HepB)
Special populations
• Administer HepB or HepA-HepB to adults with the following 
indications:
 ʱ Chronic liver disease (e.g., hepatitis C infection, cirrhosis, 
fatty liver isease, alc holic liver disease, autoimmune 
hepatitis, alanine aminotransferase [ALT] or aspartate 
aminotransferase [AST] level gr ater tha  twice the upper 
limit of normal)
 ʱ HIV i fect on
 ʱ Percutane us or mucosal risk of exposure to blood 
(e.g., household contacts of hepatitis B surface antigen 
[HBsAg]-po itive persons; adults younger than ag  60 
years with diabet s mellitus or aged 60 years or older 
with diabetes mellitus based on individual clinical decision; 
ad lts in predialysis care or receiving hemodialysis or 
peritoneal dialysis; recent or current injection drug 
users; health care and public safety workers at risk for 
exposure to blood or blood-contaminated body fluids)
 ʱ Sexual exposure risk (e.g., sex partners of HBsAg-
positive persons; sexually activ  persons not in a mutually 
monogamous relationship; persons seeking valuation or 
treatment for a sexually transmitted infection; and men 
who have sex with men [MSM])
 ʱ Receive care in settings where a high proportion of 
adults h ve risks for hepatitis B infection (e.g., facilities 
providing sexually transmitted dis ase treat ent, drug-
abuse treatment and prevention services, hemodialysis 
and end-stage renal disease programs, institutions for 
developmentally disabled persons, health care settings 
targeting services to injection drug users or MSM, HIV 
testing and treatment facilities, and correctional facilities)
 ʱ Travel to countries with high or intermediate hepatitis B 
endemicity
10. M ningococcal vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html 
Special populations: Serogroups A, C, W, and Y 
meningococcal vaccine (MenACWY)
• Administer 2 doses of MenACWY at least 8 weeks apart and 
revaccinate with 1 dose of MenACWY every 5 years, if the risk 
remains, to adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease and other hemoglobinopathies)
 ʱ HIV infection
 ʱ Persistent complement component deficiency
 ʱ Eculizumab use
• Administer 1 dose of MenACWY and revaccinate with 1 dose 
of MenACWY every 5 years, if the risk remains, to adults with 
the following indications:
 ʱ Travel to or live in countries where meningococcal 
disease is hyperendemic or epidemic, including 
countries in the African meningitis belt or during the Hajj
 ʱ At risk from a meningococcal disease outbreak 
attributed to serogroup A, C, W, or Y
 ʱ Microbiologists routinely exposed to Neisseria 
meningitidis
 ʱ Military recruits
 ʱ First-year college students who live in residential 
housing (if they did not receive MenACWY at age 16 years 
or older)
General Information: Serogroup B meningococcal vaccine 
(MenB)
 ʱ May administer, based on individual clinical decision, to 
young adults and adolescents aged 16–23 years (preferred 
age is 16–18 years) who are not at increased risk 2-dose 
series of MenB-4C (Bexsero) at least 1 month apart or 
2-dose series of MenB-FHbp (Trumenba) at least 6 months 
apart
 ʱ MenB-4C and MenB-FHbp are not interchangeable
Special populations: MenB
• Administer 2-dose series of MenB-4C at least 1 month apart 
or 3-dose series of MenB-FHbp at 0, 1–2, and 6 months to 
adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease)
 ʱ Persistent complement component deficiency
 ʱ Ecul zumab use
 ʱ At risk from a me ing occal disease outbreak 
attributed to serogroup B
 ʱ Microbi logists routinely exposed to Neisseria 
meningitidis
11.  Haemophilus influenzae type b vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html 
Special populations
• Administer Haemophilus influenzae type b vaccine (Hib) to 
adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease) or undergoing elective splenectomy: Administer 
1 dose  if not previously vaccinated (preferably at least 14 
days before elective splenectomy)
 ʱ Hematopoietic stem cell transplant (HSCT): Administer 
3-dose series with doses 4 weeks apart starting 6 to 12 
months after successful transplant regardless of Hib 
vaccination history
Special populations
• Administer to adults aged 19 through 64 years with the 
following chronic conditions 1 dose of PPSV23 (at age 65 
years or older, administer 1 dose of PCV13, if not previously 
received, and another dose of PPSV23 at least 1 year after 
PCV13 and at least 5 years after PPSV23):
 ʱ Chronic heart disease (excluding hypertension)
 ʱ Chronic lung disease
 ʱ Chronic liver disease
 ʱ Alcoholism
 ʱ Diabetes mellitus
 ʱ Cigarette smoking
• Administer to adults ag d 19 years or older with the 
following indications 1 dose of PCV13 followed by 1 dose of 
PPSV23 at le st 8 w eks after PCV13, and a second dose of 
PPSV23 at least 5 years after the first dose of PPSV23 (if the 
most recent dose of PPSV23 was administered before age 65 
years, at age 65 years or older, administer another dose of 
PPSV23 at least 5 years after the last dose of PPSV23):
 ʱ Immunodeficiency disorders (including B- and 
T-lymphocyte deficiency, complement deficiencies, and 
phagocy c disorders)
 ʱ HIV infection
 ʱ Anat mical or functional asplenia (including sickle cell 
disease and other hemoglobinopathies) 
 ʱ Chronic renal failure and n phrotic syndrome
• Administer to adults aged 19 years or older with the 
following indica ions 1 dose of PCV13 followed by 1 dose of 
PPSV23 at least 8 weeks after PCV13 (if the dose of PPSV23 
was administered before age 65 years, at age 65 years or 
older, administer another dose of PPSV23 at least 5 years 
after the last dose of PPSV23):
 ʱ Cerebrospinal fluid leak
 ʱ Cochlear implant
8. Hepatitis A vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html 
General information
• Administe  to adults who have a sp cific isk (see below), 
or lack a risk factor but wa  protection, 2-dose ser es of 
single antigen hepatitis A vaccin  (HepA; Havrix at 0 and 
6–12 months or Vaqta at 0 an  6–18 months; minimum 
interval: 6 months) or a 3-dose series of combined hepatitis 
A and hepatitis B vaccine (HepA-HepB) at 0, 1, and 6 months; 
minimum intervals: 4 weeks between first and second doses, 
5 months between second and third doses
Special populations
• Administer He A or HepA-HepB to adults with the following 
ndica ions:
 ʱ Travel t  or work in countries with high or intermediate 
hepatitis A endemicity 
 ʱ Men who have sex with men
 ʱ Injection or noninjection drug use
 ʱ Work with hepatitis A virus in a research laboratory 
or with nonhuman primates infected with hepatitis A 
virus
 ʱ Clotting factor disorders
 ʱ Chronic liver disease
 ʱ Close, personal contact with an international adoptee 
(e.g., household or regular babysitting) during the first 60 
days after arrival in the United States from a country with 
high or intermediate endemicity (administer the first dose 
as soon as the adoption is planned)
 ʱ Healthy adults through age 40 years who have recently 
been exposed to hepatitis A virus; adults older than age 
40 years may receive HepA or HepA-HepB if hepatitis A 
immunoglobulin cannot be obtained
9. Hepatitis B vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html 
General information
• Administer to dults who have a specific risk (see below), or 
lack a risk factor but want protection, 3-dose series of single 
antigen hepatitis B vaccine (HepB) or combined hepatitis A 
and hepatitis B vaccine (HepA-HepB) at 0, 1, and 6 months 
(minimum intervals: 4 weeks between doses 1 and 2 for 
HepB and HepA-HepB; between doses 2 and 3, 8 weeks for 
HepB and 5 months for HepA-HepB)
Special populations
• Administer HepB or HepA-HepB to adults with the following 
indications:
 ʱ Chronic liver disease (e.g., hepatitis C infection, cirrhosis, 
fatty liver disease, alcoholic liver disease, autoimmune 
hepatitis, alanine aminotransferase [ALT] or aspartate 
aminotransferase [AST] level greater than twice the upper 
limit of normal)
 ʱ HIV infection
 ʱ Percutaneous or mucosal risk of exposure to blood 
(e.g., household contacts of hepatitis B surface antigen 
[HBsAg]-positive persons; adults younger than age 60 
years with diabetes mellitus or aged 60 years or older 
with diabetes mellitus based on individual clinical decision; 
adults in predialysis care or receivin  hemodialysis or 
peritoneal dialysis; recent or current i jection drug 
users; health care and public sa ety workers at risk for 
exposure to blood or blood-co taminated body fluids)
 ʱ Sexual exposure risk (e.g., sex partners of HBsAg-
positive persons; sexually active persons not in a mutually 
monogamous relations ip; perso s seeking evaluation or 
treatment for a sexually transmitted infection; and m n 
who h ve sex with me  [MSM])
 ʱ Receive care in set i gs wher  a high prop rtion of 
adults have risks for hepatitis B infection (e.g., facilities 
providing sexually transmitted disease treatment, drug-
abuse treatment and prevention services, hemodialysis 
and end-stage renal disease programs, institutions for 
dev lopmentally disabl d persons, health care settings 
targeting services to i j ction drug users or MSM, HIV 
test ng and treatment fac lities, and correctional facilities)




Special populations: Serogroups A, C, W, and Y 
meningococcal vaccine (MenACWY)
• Administer 2 doses of MenACWY at least 8 weeks apart and 
revaccinate with 1 dose of MenACWY every 5 years, if the risk 
remains, to adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease and other hemoglobinopathies)
 ʱ HIV infection
 ʱ Persistent complement component deficiency
 ʱ Eculizumab use
• Administer 1 dose of MenACWY and revaccinate with 1 dose 
of MenACWY ev ry 5 years, if the risk remains, to adults with 
the following indications:
 ʱ Tra el to or live  countri s where mening coccal 
disease is hyperend mic or epid m c, including 
countries in the African m ningitis belt or during the Hajj
 ʱ At risk fro  a meningococcal disease outbreak 
attribu ed to serogroup A, C, W, or Y
 ʱ Microbiologists routinely exposed to Neisseria 
meningitidis
 ʱ Military recruits
 ʱ First-year college students who live in residential 
housing (if they did not receive MenACWY at age 16 years 
or older)
General Information: Serogroup B m ningococcal vaccine 
(MenB)
 ʱ May administer, based on individual clinical decision, to 
young adults and adolescents aged 16–23 years (preferred 
age is 16–18 years) who are not at increased risk 2-dose 
series of MenB-4C (Bexsero) at least 1 month apart or 
2-dose series of MenB-FHbp (Trumenba) at least 6 months 
apart
 ʱ MenB-4C and MenB-FHbp are not interchangeable
Special populations: MenB
• Administer 2-dose series of MenB-4C at least 1 month apart 
or 3-dose series of MenB-FHbp at 0, 1–2, and 6 months to 
adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease)
 ʱ Persistent complement component deficiency
 ʱ Eculizumab use
 ʱ At risk from a meningococcal disease outbreak 
attributed to serogroup B
 ʱ Microbiologists routinely exposed to Neisseria 
meningitidis
11.  Haemophilus influenzae type b vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html 
Special populations
• Administer Haemophilus influenzae type b vaccine (Hib) to 
adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease) or undergoing elective splenectomy: Administer 
1 dose  if not previously vaccinated (preferably at least 14 
days before elective splenectomy)
 ʱ Hematopoietic stem cell transplant (HSCT): Administer 
3-dose series with doses 4 weeks apart starting 6 to 12 
months after successful transplant regardless of Hib 
vaccination history
Special populations
• Administer to adults aged 19 through 64 years with the 
following chronic conditions 1 dose of PPSV23 (at age 65 
years or older, administer 1 dose of PCV13, if not previously 
received, and another dose of PPSV23 at least 1 year after 
PCV13 and at least 5 years after PPSV23):
 ʱ Chronic heart disease (excluding hypertension)
 ʱ Chronic lung disease
 ʱ Chronic liver disease
 ʱ Alcoholism
 ʱ Diabetes mellitus
 ʱ Cigarette smoking
• Administer to adults ag d 19 years or older with the 
following indications 1 dose of PCV13 followed by 1 dose of 
PPSV23 at least 8 weeks after PCV13, and a second dose of 
PPSV23 at least 5 years after the first dose of PPSV23 (if the 
most recent dose of PPSV23 was administered before age 65 
years, at age 65 years or older, administer another dose of 
PPSV23 at least 5 years after the last dose of PPSV23):
 ʱ Immunodeficiency disorders (including B- and 
T-lymphocyte deficiency, complement deficiencies, and 
phagocytic disorders)
 ʱ HIV i fection
 ʱ An tomical or functional asplenia (including sickle cell 
disease and other hem globinopathies) 
 ʱ Chronic renal failure and nephrotic syndr me
• Administer to adults aged 19 years or older with the 
following indications 1 dose of PCV13 followed by 1 dose of 
PPSV23 at least 8 weeks after PCV13 (if the dose of PPSV23 
was administered before age 65 years, at age 65 years or 
olde , administer an ther dose of PPSV23 at least 5 years 
aft r the last dose of PPSV23):
 ʱ Cerebr spin l fluid leak
 ʱ C chl ar implant
8. Hepatitis A vaccination
www.cdc.g v/vaccines/hcp/acip-recs/vacc-specific/hepa.html 
General information
• Administer to adults who have a specific risk (see below), 
or lack a risk factor but want protection, 2-dose series of 
single antigen hepatitis A vaccine (HepA; Havrix at 0 and 
6–12 months or Vaqta at 0 and 6–18 months; minimum 
interval: 6 months) or a 3-dose series of combined hepatitis 
A and hepatitis B vaccine (HepA-HepB) at 0, 1, and 6 months; 
minimum intervals: 4 weeks between first and second doses, 
5 months between second and third doses
Special populatio s
• Administer HepA or HepA-H B t  adults with the following 
indications:
 ʱ Travel to or work in countries with high or intermediate 
hep titis A endemicity 
ʱ Men who have sex with men
 ʱ Injection or noninjection drug use
 ʱ Work with hepatitis A virus in a research laboratory 
or with nonhuman primates infected with hepatitis A 
virus
 ʱ Cl tting factor disorders
 ʱ Chronic liver disease
 ʱ Close, personal contact with an international adoptee 
(e.g., household or regular babysitting) during the first 60 
days after arrival in the United States from a country with 
high or intermediate endemicity (administer the first dose 
as soon as the adoption is planned)
 ʱ Healthy adults through age 40 years who have recently 
been exposed to hepatitis A virus; adults older than age 
40 years may receive HepA or HepA-HepB if hepatitis A 
immunoglobulin cannot be obtained
9. Hepatitis B vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html 
General information
• Administer to adults who have a specific risk (see below), or 
lack a risk factor but want protection, 3-dose series of single 
antigen hepatitis B vaccine (HepB) or combined hepatitis A 
and hepatitis B vaccine (HepA-HepB) at 0, 1, and 6 months 
(minimum intervals: 4 weeks between doses 1 and 2 for 
HepB and HepA-HepB; between doses 2 and 3, 8 weeks for 
HepB and 5 months for HepA-HepB)
Special populations
• Administer HepB or HepA-HepB to adults with the following 
indications:
 ʱ Chr nic liver disease (e.g., hepatitis C infection, cirrhosis, 
fatty liver disease, alcoholic liver disease, autoimmune 
hepatitis, alanine aminotransferase [ALT] or aspartate 
ami otransferase [AST] level greater than twice the upper 
limit of n rmal)
ʱ HIV infection
 ʱ P rc taneous or mucosal risk of ex osur  to blood 
(e.g., household contacts of hepatitis B surface antigen 
[HBsAg]-positive persons; adults younger than age 60 
years with diabetes mellitus or aged 60 years or older 
with diabetes mellitus based on individual clinical decision; 
dults in predi lysis care or receiving hemodialysis or 
peritone l dialysis; recent or current inj ction d ug 
users; health care and public safety work r  at risk for 
exposure to blood or blood-contaminated body fluids)
ʱ S xual exposure risk (e.g., sex p rtners of HBsAg-
positive persons; sexually activ  persons not in a mutually 
monogamous relationship; per ons seeking evaluati n or 
treatment for a sexually transmitted infection; and men 
who have sex with men [MSM])
 ʱ Receive care in settings where a high proportion of 
adults have risks for hepatitis B infection (e.g., facilities 
providing sexually transmitted disease treatment, drug-
abuse treatment and prevention services, hemodialysis 
and end-stage renal disease programs, institutions for 
developmentally disabled persons, health care settings 
targeting services to injection drug users or MSM, HIV 
testing and treatment facilities, and correctional facilities)
 ʱ Travel to countries with high or intermediate hepatitis B 
endemicity
10. Menin oc ccal vaccination
www.cdc.g v/vaccines/hcp/acip-recs/vacc-specific/mening.html 
Special populations: Serogroups A, C, W, and Y 
meningococcal vaccine (MenACWY)
• Administer 2 doses of MenACWY at least 8 weeks apart and 
revaccinate with 1 dose of MenACWY every 5 years, if the risk 
remains, to adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease and other hemoglobinopathies)
 ʱ HIV infection
 ʱ Persistent complement component deficiency
 ʱ Eculizumab use
• Administer 1 dose of MenACWY and revaccinate with 1 dose 
of MenACWY every 5 years, if the risk remains, to adults with 
the following indications:
 ʱ Travel to or live in countries where meningococcal 
disease is hyperendemic or epidemic, including 
countries in the African meningitis belt or during the Hajj
 ʱ At risk from a meningococcal disease outbreak 
attributed to serogroup A, C, W, or Y
 ʱ Microbiologists routinely exposed to Neisseria 
meningitidis
 ʱ Military recruits
 ʱ First-year college students who live in residential 
housing (if they did not receive MenACWY at age 16 years 
or older)
General Information: Serogroup B meningococcal vaccine 
(MenB)
 ʱ May administer, based on individual clinical decision, to 
young adults and adolescents aged 16–23 years (preferred 
age is 16–18 years) who are not at increased risk 2-dose 
series of MenB-4C (Bexsero) at least 1 month apart or 
2-dose series of MenB-FHbp (Trumenba) at least 6 months 
apart
 ʱ MenB-4C and MenB-FHbp are not interchangeable
Special populations: MenB
• Administer 2-dose series of MenB-4C at least 1 month apart 
or 3-dose series of MenB-FHbp at 0, 1–2, and 6 months to 
adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease)
 ʱ Persistent complement component deficiency
 ʱ Eculizumab use
 ʱ At risk from a meningococcal disease outbreak 
attributed to serogroup B
 ʱ Microbiologists routinely exposed to Neisseria 
meningitidis
11.  Haemophilus nflu nzae type b vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html 
Special populations
• Administer Haemophilus influenz e type b vaccine (Hib) to 
adults with the following indications:
 ʱ Anatomical or functional aspleni  ( ncluding sickle cell 
disease) or undergoing elective splenectomy: Administer 
1 dose  if not previ usly vaccinat d (preferably at least 14 
days before elective splenectomy)
 ʱ Hematopoietic stem cell transplant (HSCT): Administer 
3-dose series with doses 4 weeks apart starting 6 to 12 
months after successful transplant regardless of Hib 
vaccination history
Vaccine(s) Additional Contraindications Additional Precautions
IIV1 • History of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination
• Egg allergy other than hives, e.g., angioedema, respiratory distress, lightheadedness, or recurrent 
emesis; or required epinephrine or another emergency medical intervention (IIV may be 
administered in an inpatient or outpatient medical setting and under the supervision of a health 
care provider who is able to recognize and manage severe allergic conditions)
RIV1 • History of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination
Tdap, Td • For pertussis-contai ing vaccines: encephalopathy, e.g., coma, decreased level of consciousness, 
or prolonged seizures, not attributable to another identifiable cause within 7 days of 
administration of a previous dose of a vaccine containing tetanus or diphtheria toxoid or acellular 
pertussis
• Guillain-Barré syndrome within 6 weeks after a previous dose of tetanus toxoid-containing 
vaccine
• History of Arthus-type hypersensitivity reactions after a previous dose of tetanus or diphtheria 
toxoid-containing vaccine. Defer vaccination until at least 10 years have elapsed since the last 
tetanus toxoid-containing vaccine
• For pertussis-containing vaccine, progressive or unstable neurologic disorder, uncontrolled 
seizures, or progressive encephalopathy (until a treatment regimen has been established and the 
condition has stabilized)
MMR2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, human immunodeficiency virus 
(HIV) infection with severe immunocompromise
• Pregnancy
• Recent (within 11 months) receipt of antibody-containing blood product (specific interval 
depends on product)4
• History of thrombocytopenia or thrombocytopenic purpura
• Need for tuberculin skin testing5
VAR2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, HIV infection with severe 
immunocompromise
• Pregnancy
• Recent (within 11 months) receipt of antibody-containing blood product (specific interval 
depends on product)4
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before 
vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
ZVL2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, HIV infection with severe 
immunocompromise
• Pregnancy
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before 
vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
HPV vaccine • Pregnancy
PCV13 • Severe allergic reaction to any vaccine containing diphtheria toxoid
1. For additional information on use of influenza vaccines among persons with egg allergy, see: CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization 
Practices—United States, 2016–17 influenza season. MMWR. 2016;65(RR-5):1–54. Available at www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm.
2. MMR may be administered together with VAR or ZVL on the same day. If not administered on the same day, separate live vaccines by at least 28 days. 
3. Immunosuppressive steroid dose is considered to be daily receipt of 20 mg or more prednisone or equivalent for 2 or more weeks. Vaccination should be deferred for at least 1 month after discontinuation of 
immunosuppressive steroid therapy. Providers should consult ACIP recommendations for complete information on the use of specific live vaccines among persons on immune-suppressing medications or with immune 
suppression because of other reasons.
4. Vaccine should be deferred for the appropriate interval if replacement immune globulin products are being administered. See: Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at 
www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html. 
5. Measles vaccination may temporarily suppress tuberculin reactivity. Measles-containing vaccine may be administered on the same day as tuberculin skin testing, or should be postponed for at least 4 weeks after vaccination.
Table. Contraindications and precautions for vaccines recommended for adults aged 19 years or older*
The Advisory C mitte  on Immunization Practices (ACIP) recom endations and package inserts for vaccines provide information on contraindications and precautions related to vaccines. Contraindications are conditions 
that increase cha ces of a ser ous dverse reaction in v ccine cipie ts and the vaccine should not be administered when a contraindication is present. Precautions should be reviewed for potential risks and benefits for vaccine 
recipients. 
Vaccine(s) Contraindications Precautions
All vaccines routinely 
recomme ded f r adults
• Sever  reacti n, e.g., anaphylaxis, after a previous dos  or to a vaccine component • Moderate or severe acute illness with or without fever
Additional contraindications and precautions for vaccines routinely recommended for adults
Contraindications and precautions for vaccines routinely recommended for adults
*  Adapted from: CDC. Table 6. Contraindications and precautions to commonly used vaccines. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR. 
2011;60(No. RR-2):40–1 and from: Hamborsky J, Kroger A, Wolfe S, eds. Appendix A. Epidemiology and prevention of vaccine preventable diseases. 13th ed. Washington, DC: Public Health Foundation, 2015. Available at www.cdc.
gov/vaccines/pubs/pinkbook/index.html. 
Abbreviations of vaccines
IIV inactivated influenza vaccine
RIV recombinant influenza vaccine
Tdap  tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis vaccine
Td  tetanus and diphtheria toxoids
MMR  measles, mumps, and rubella vaccine
VAR varicella vaccine
RZV recombinant zoster vaccine
ZVL zoster vaccine live
HPV vaccine human papillomavirus vaccine
PCV13  13-valent pneumococcal conjugate vaccine 
PPSV23  23-valent pneumococcal polysaccharide vaccine
HepA hepatitis A vaccine
HepA-HepB hepatitis A and hepatitis B vaccines
HepB hepatitis B vaccine
MenACWY serogroups A, C, W, and Y meningococcal vaccine
MenB  serogroup B meningococcal vaccine
Hib  Haemophilus influenzae type b vaccine
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Vaccine(s) Additional Contraindications Additional Precautions
IIV1 • History of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination
• Egg allergy other than hives, e.g., angioedema, respiratory distress, lightheadedness, or recurrent 
emesis; or required epinephrine or another emergency medical intervention (IIV may be 
administered in an inpatient or outpatient medical setting and under the supervision of a health 
care provider who is able to recognize and manage severe allergic conditions)
RIV1 • History of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination
Tdap, Td • For pertussis-co taining vaccines: encephalopathy, e.g., coma, decreased level of consciousness, 
or prolonged seizures, ot ttributable to another identifiable cause within 7 days of 
administration of a previous dose of a vaccine containing tetanus or diphtheria toxoid or acellular 
pertussis
• Guillain-Barré syndrome within 6 weeks after a previous dose of tetanus toxoid-containing 
vaccine
• History of Arthus-type hypersensitivity reactions after a previous dose of tetanus or diphtheria 
toxoid-containing vaccine. Defer vaccination until at least 10 years have elapsed since the last 
tetanus toxoid-containing vaccine
• For pertussis-containing vaccine, progressive or unstable neurologic disorder, uncontrolled 
seizures, or progressive encephalopathy (until a treatment regimen has been established and the 
condition has stabilized)
MMR2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, human immunodeficiency virus 
(HIV) infection with severe immunocompromise
• Pregnancy
• Recent (within 11 months) receipt of antibody-containing blood product (specific interval 
depends on product)4
• History of thrombocytopenia or thrombocytopenic purpura
• Need for tuberculin skin testing5
VAR2 • S vere i mu odefici n y, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, HIV infection with severe 
immunocompromise
• Pregnancy
• Recent (within 11 months) receipt of antibody-containing blood product (specific interval 
depends on product)4
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before 
vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
ZVL2 • Sev re immunodefici ncy, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, HIV infection with severe 
immunocompromise
• Pregnancy
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before 
vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
HPV vaccine • Pregnancy
PCV13 • Severe allergic reaction to any vaccine containing diphtheria toxoid
1. For additional information on use of influenza vaccines among persons with egg allergy, see: CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization 
Practices—United States, 2016–17 influenza season. MMWR. 2016;65(RR-5):1–54. Available at www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm.
2. MMR may be administered together with VAR or ZVL on the same day. If not administered on the same day, separate live vaccines by at least 28 days. 
3. Immunosuppressive steroid dose is considered to be daily receipt of 20 mg or more prednisone or equivalent for 2 or more weeks. Vaccination should be deferred for at least 1 month after discontinuation of 
immunosuppressive steroid therapy. Providers should consult ACIP recommendations for complete information on the use of specific live vaccines among persons on immune-suppressing medications or with immune 
suppression because of other reasons.
4. Vaccine should be deferred f r the appropriate interval if replacement immune globulin products are being administered. See: Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at 
www.c c.gov/vaccines/hcp/acip-recs/gener l-recs/index.html. 
5. Measles vaccinati n may tempor rily suppr ss tub rculin reactivity. Measles-containing vaccine may be administered on the same day as tuberculin skin testing, or should be postponed for at least 4 weeks after vaccination.
Table. Co train ications and precautio s for vaccin s recommended for adults aged 19 years or older*
The Advisory Committee on Immunization Practices (ACIP) recommendations and package inserts for vaccines provide information on contraindications and precautions related to vaccines. Contraindications are conditions 
that increase chances of a serious adverse reaction in vaccine recipients and the vaccine should not be administered when a contraindication is present. Precautions should be reviewed for potential risks and benefits for vaccine 
recipients. 
Vaccine(s) Contraindications Precautions
All vaccines routinely 
recommended for adults
• Severe reaction, e.g., anaphylaxis, after a previous dose or to a vaccine component • Moderate or severe acute illness with or without fever
Additional contraindications and precautions for vaccines routinely recommended for adults
Contraindications and precautions for vaccines routinely recommended for adults
*  Adapted from: CDC. Table 6. Contraindications and precautions to commonly used vaccines. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR. 
2011;60(No. RR-2):40–1 and from: Hamborsky J, Kroger A, Wolfe S, eds. Appendix A. Epidemiology and prevention of vaccine preventable diseases. 13th ed. Washington, DC: Public Health Foundation, 2015. Available at www.cdc.
gov/vaccines/pubs/pinkbook/index.html. 
Abbreviations of vaccines
IIV inactivated influenza vaccine
RIV recombinant influenza vaccine
Tdap  tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis vaccine
Td  tetanus a d diphth ria toxoids
MMR  measles, mum s, and rubella vaccine
VAR varicella vaccine
RZV recombinant zoster vaccine
ZVL zoster vaccine live
HPV vaccine human papillomavirus vaccine
PCV13  13-valent pneumococcal conjugate vaccine 
PPSV23  23-valent pneumococcal polysaccharide vaccine
HepA hepatitis A vaccine
HepA-HepB hepatitis A and hepatitis B vaccines
HepB hepatitis B vaccine
MenACWY serogroups A, C, W, and Y meningococcal vaccine
MenB  serogroup B meningococcal vaccine
Hib  Haemophilus influenzae type b vaccine
CS270457-A
Vaccine(s) Addi ional Contraindications Additional Precautions
IIV1 • History of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination
• Egg allergy other than hives, e.g., angioedema, respiratory distress, lightheadedness, or recurrent 
emesis; or required epi ephrine or another emergency medical intervention (IIV may be 
administered in an inpatient or outpatient medical setting and under the supervisi n of a health 
care provider who is able to recognize and manage severe allergic conditions)
RIV1 • History of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination
Tdap, Td • For pertussis-containing vaccines: encephalopathy, e.g., coma, decrease  level of consciousness, 
or prolonged seizures, not attributable to another identifiable cause within 7 days of 
administration of a previous dose of a vaccine containing tetanus or diphtheria toxoid or acell lar 
pertussis
• Guillain-Barré syndrome within 6 weeks after a previous dose of tetanus toxoid-containing 
vaccine
• History of Arthus-type hypersensitivity rea tions aft r a previous dose of tetanus or diphtheria 
toxoid-containing vaccine. Defer vaccination until at least 10 years have elapsed since the last 
t tanus toxoid- ntaining vaccine
• For pertussis-containing vaccine, progressive or unstable neurologic disorder, uncontrolled 
s izur s, or progressive encephalopathy (until a treatment regimen has been established and the 
condition has stabilized)
MMR2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chem therapy, co enital 
im unodeficie cy or long-term immunosuppressive therapy3, human immunodeficie cy virus 
(HIV) infection with sev re immunocompromise
• Pr gnancy
• Recent (within 11 months) receipt of antibody-containing blood product (specific int rval 
depends on product)4
• History of thro b cytope ia r thro bocytopenic pur ura
• Need for tuberculi  skin testing5
VAR2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long- erm immunosuppressive therapy3, HIV infection with severe 
immunocompromise
• Pregnancy
• Recent (within 11 months) receipt of antibody-containing blood product (specific interval 
depends on product)4
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before 
v ccination (avoid use of these antiviral drugs for 14 days after vaccination)
ZVL2 • Severe immu od fici ncy, e.g., hematologic and solid tumors, chem therapy, conge ital 
immunodeficiency or long-term immu osuppressive therapy3, HIV infection with severe 
immunocompromise
• Pregnancy
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before 
vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
HPV vaccine • Pr gnancy
PCV13 • Severe allergic reaction to any vaccine containing diphtheria tox id
1. For additional information on use of influenza vaccines among persons with egg allergy, see: CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization 
Practices—United States, 2016–17 influenza season. MMWR. 2016;65(RR-5):1–54. Available at www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm.
2. MMR ay be administered together with VAR or ZVL on the same day. If not administered on the same day, separate live ccines by at least 28 days. 
3. Immunosuppressive steroid dose is considered to be daily receipt of 20 mg or more prednison  or equivalent or 2 or more weeks. Vaccination should be deferred for at least 1 month after discontinuation of 
immunosuppressive steroid therapy. Providers should consult ACIP recommendations for complete inf rmation on the use of specific live vaccines among persons on immune-suppressing medications or with immune 
suppression because of other reasons.
4. Vaccine sho ld be deferred for th  appropriate interval if replacement immune globulin products are b ing administered. See: Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at 
www.cdc.gov/vaccines/hcp/acip-recs/general-recs/i dex.html. 
5. Measles vaccination may temporarily suppres  tuberculin reactivity. Measles-containing vaccine may be administered on the same day as tuberculin skin testing, or should be postponed for at least 4 weeks after vaccination.
Table. Contraindications and precautions for vaccines recommended fo  adults aged 19 years or lde *
The Advisory Committee on Immu ization Practices (ACIP) recommendations and pack ge in erts for vaccines provide information on contraindic tions and precautions related to vac ines. Contraindications are c nditions
that increase chances of a serious adverse reac ion i  vaccine recipients and the vaccine shoul  not be administered when a contraindication is present. Precautions should be reviewed for potential risks and benefits for vaccine 
recipients. 
Vaccine(s) Contraindications Precautions
All vaccines routinely 
recommended for a ults
• Severe reaction, e.g., anaphylaxis, after a previous dose or to a vaccine component • Moderate or severe acute illness with or without fever
Additional contraindicatio s nd precautions for vacci es routinely recom e ded for adults
Contraindications and precautions for vaccines routinely recommended for adults
*  Adapte  from: CDC. Tabl  6. Contr i dicati ns and precautions to commonly used vaccines. Gen ral recomme dations on immunization: recommendations of the Advisory Committee o  Immunization Practices. MMWR. 
2011;60(No. RR-2):40–1 nd fr m: Hamborsky J, Kroger A, W lfe S, eds. Appendix A. Epidemiology and prevention of vaccine preventable diseases. 13th ed. Washington, DC: Public Health Fou dation, 2015. Available at www.cdc.
gov/vaccines/pubs/pinkbook/index.html. 
Abbreviations of vaccines
IIV inactiv ted influenza vaccine
RIV reco bin nt influenza vaccine
Tdap  tetanus toxoid, reduced diphtheria tox id, and 
acellular per ussis v cine
Td  t tanus a d diphtheria tox ids
MMR  measles, mumps, and rubella vaccine
VAR varicella vaccine
RZV recombinant zoster vaccine
ZVL zoster vaccine live
HPV vaccine human papillomavirus vaccine
PCV13  13-valent pneumococcal conjugate vacci e 
PPSV23  23-valent pneumococcal polysaccharide vaccine
HepA hepatitis A vaccine
HepA-HepB hepatitis A and hepatitis B vaccines
HepB hepatitis B vaccine
MenACWY serogroups A, C, W, and Y meningococcal vaccine
MenB  serogroup B meningococcal vaccine
Hib  Haemophilus influenzae type b vaccine
CS270457-A
Vaccine(s) Additional Contraindications Additional Precautions
IIV1 • History of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination
• Egg allergy other than hives, e.g., angioedema, respiratory distress, lightheadedness, or recurrent 
emesis; or required epinephrine or another emergency medical intervention (IIV may be 
administ red in an inpatient or outpatient medical setti  a  under the supervision of a health 
car  provider who is able to recognize and m nage severe allergi  c ditio s)
RIV1 • History of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination
Tdap, Td • For pertussis-containing vaccines: encephalopathy, e.g., coma, decreased level of consciousness, 
or prolonged seizures, not attributable to another identifiable cause within 7 days of 
administration of a previous dose of a vaccine containing tetanus or diphtheria toxoid or acellular 
pertussis
• Guillain-Barré syndrome within 6 weeks after a previous dose of tetanus toxoid-containing 
vaccine
• History of Arthus-type hypersensitivity reactions after a previous dose of t tanus or dip theria 
toxoid-containing vaccine. Defer vaccinatio  until at least 10 years have elaps d since the last 
tetan s toxoid-c ntaining vaccine
• For pertussis-containing vaccine, progressive or unstable ne rologic disorde , u c ntroll d 
seizures, or progressive encephalopathy (until a treatment regimen has been established and the 
condition has stabilized)
MMR2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chem therapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, human immunodeficiency virus 
(HIV) i fection with severe im unoc mpromise
• Pregnancy
• Recent (within 11 months) receipt of antibody-containing blood product (specific interval 
depends on product)4
• History of thrombocytopenia or thrombocytop nic urpura
• Need for tuberculin skin testing5
VAR2 • Severe immunodeficiency, e.g., hematologic and solid tumor , ch motherapy, congenital 
immunodeficiency or long-term immunosuppressive t erapy3, HIV inf ction with severe 
immunoco promise
• Pregnancy
• Rece  (within 11 months) receipt of ntibody-c ntai ing blood produ t (specific interva  
dep nds on product)4
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or val yclovir) 24 hours efore 
vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
ZVL2 • Severe imm nodeficiency, e.g., hematologic and solid tumors, hemotherapy, ongenital 
i munodeficiency or long-term immuno uppressive therapy3, HIV inf tion with severe 
immunocompromise
• Pregnancy
• Rec ipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before 
vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
HPV vaccine • Pr gnancy
PCV13 • Severe allergic reaction to any vaccine containing diphtheria toxoid
1. For additional information on use of influenza vaccines among persons with egg allergy, see: CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Co mittee on Immunization 
Practices—United States, 2016–17 influenza seaso . MMWR. 2016;65(RR-5):1–54. Available at www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm.
2. MMR may be administered together wit  VAR or ZVL on the same day. If not administered on the same day, separate live vaccines by at least 28 days. 
3. Immunosuppressive steroid d se is considered to be daily receipt of 20 mg or more prednisone or equivalent for 2 or more weeks. Vaccination should be deferred for at l as  1 month after discontinuation of 
immunosuppressive steroid therapy. Providers should consult ACIP recommendations for complete information on the use of specific live vaccines among persons on immune-suppressing medications or with immune 
suppression because of other reasons.
4. Vaccine should be deferred for the appropriate interval if replacement immune globulin products are being administered. See: Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at 
www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html. 
5. Measles vaccination may temporarily suppress tuberculin reactivity. Measles-containing vaccine may be administered on the same day as tuberculin skin testing, or should be postponed for at least 4 weeks after vaccination.
Table. Co tra ndications and precautio s for vaccines recommend d for adults aged 19 years or older*
The Advisory Committee on Immunization Practices (ACIP) recommendations and package inserts for vaccin s provide information on contraindications and precauti ns related t  vaccines. Contraindications are conditions
that increase c ances of a serious adverse reaction in vaccine recipi nt  and the vaccine should not b  administered when a contraindication is present. Precautions should be eviewed for p tential risks a d benefits for va  
recipients. 
Vaccine(s) Contraindications Precautions
All vaccines routi ely 
recommended for adults
• Severe reaction, e.g., anaphylaxis, after a previous dose or to a vaccine component • Moderate or severe acute illness with or without fever
Additional contraindications and precautions for vaccines routinely recom ended f r adults
Contraindications and precautions for vaccines routinely recommended for adults
*  Adapted from: CDC. Table 6. Contraindications and precautions to commonly used vaccines. General recommen ations on immunization: recommendations of the Advisory C mittee on Immunization Practices. MMWR. 
2011;60(No. RR-2):40–1 and fr m: Hamborsky J, Kroger A, Wolfe S, eds. Appendix A. Epidemiology and prevention of vaccine preventable diseases. 13th ed. Washington, DC: Public Health Foundation, 2015. Available at www.cdc.
gov/vaccines/pubs/pinkbook/index.html. 
Abbreviations of vaccines
IIV inactivated influenza vaccine
RIV recombinant influenza vaccine
Tdap  tetanus toxoid, reduced diphth ria toxoid, and 
acellular pertussis vaccine
Td  tetanus and diphtheria toxoids
MMR  measle , mumps, and rubella vacci e
VAR varicella vaccine
RZV recombinant zoster vaccine
ZVL zoster vaccine live
HPV vaccine human papillomavirus vaccine
PCV13  13-v lent pneumococcal conjugate vaccine 
PPSV23  3-valent pn umococcal polysaccharide v ccine
HepA hep titis A vaccine
HepA-HepB hepatitis A and hepatitis B vaccines
HepB hepatitis  vaccine
MenACWY serogroups A, C, W, and Y meningococcal vaccine
MenB  serogroup B mening coccal vaccin
Hib  Haemophilus influenzae type b vaccine
CS270457-A
